Skip to Content
Authors Rademacher BL, Matkowskyj KA, Meske LM, Romero A, Sleiman H, Carchman EH
Author Profile(s)
Journal Virology Volume: 507 Pages: 82-88
Publish Date 2017 Jul
PubMed ID 28431282
PMC ID 5584602
Abstract

Autophagy is an intracellular, catabolic process that maintains cellular health. We examined the response of pharmacologic modulation of autophagy in an HPV mouse model of anal carcinogenesis. K14E6/E7 mice were treated with the topical carcinogen DMBA weekly and assessed for tumors over 20 weeks. Concurrently, they were given either chloroquine or BEZ235, to inhibit or induce autophagy, respectively. Time to tumor onset was examined. Immunofluorescence (IF) was performed for LC3β and p62 to examine autophagy. All DMBA treated K14E6/E7 mice developed anal cancer, contrary to zero of the no DMBA treated mice. Chloroquine plus DMBA resulted in a significant decrease in the time to tumor onset compared to K14E6/E7 treated with DMBA. Only 40% BEZ235 plus DMBA treated mice developed anal cancer. Autophagic induction with DMBA and BEZ235, and autophagic inhibition with chloroquine were confirmed via IF. Anal carcinogenesis can be inhibited or induced via pharmacologic modulation of autophagy.

Full Text Full text available on PubMed Central
webmaster@surgery.wisc.edu Copyright © 2017 The Board of Regents of the University of Wisconsin System